Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-15

Investor-Webinar this morning:

- No need for a CR for operational purposes as break even or better has become a reality
- No need for a CR in case of "upscaling" as contracted manufacturer have enough capacity for more orders
- No share consolidation considered at this stage


The ordered devices for AZ are now in the process of getting installed and once fully operational and evaluated they will be used as a show case for other pharmas which, atm, are awaiting those results to make a purchase decision.

It looks that we can expect more sales to be announced in 2H'25, maybe earlier, depending on the AZ evaluation.

IMO, all looks great. MC of about AUD 30m doesn't reflect the achievements at all - great buying at this stage for those who can be patient for 12 months. As the sales will come in throughout the year the best way to look at them is on an annual basis, they may sell 5 units in Q2'25, then none in Q3'25 and maybe 6 in Q4'25.

There are so many companies on the ASX valued in 100s of Millions or even Billions with no or not cost covering income, compared to those CC5 is almost a NON-RISK investment.

I will take advantage of any dumping, there could be a huge reward coming by the end of this year when the bigger pockets become aware of CC5.

GLTA